Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis
Unknown status
Azidus Brasil
Phase 3
2011-02-01
The primary objective of this study is to evaluate, through clinical parameters, the
effectiveness of your medicine topic Maxinom ® (dexamethasone, neomycin and polymyxin B -
Union Chemicals), comparing it to the topical medication Maxitrol ® (dexamethasone, neomycin
and polymyxin B - Alcon ) by the percentage of improvement (sustained response rate) at the
end of treatment, among the products studied.
Suture Contamination Rate in Adjustable Suture Strabismus Surgery
Completed
Bascom Palmer Eye Institute
N/A
2015-07-01
1. To establish the culture positivity rate in adjustable suture strabismus surgery
2. To identify bacterial species and antibiotic susceptibility patterns of microorganisms
cultured from suture material
3. To compare suture contamination rates with techniques to reduce the suture contamination
rate
Suture Contamination Rate in Adjustable Suture Strabismus Surgery
Completed
University of Miami
N/A
2015-07-01
1. To establish the culture positivity rate in adjustable suture strabismus surgery
2. To identify bacterial species and antibiotic susceptibility patterns of microorganisms
cultured from suture material
3. To compare suture contamination rates with techniques to reduce the suture contamination
rate
Sponsor Type for DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Sponsor
Trials
Other
2
Industry
1
[disabled in preview]
0
This preview shows a limited data set Subscribe for full access, or try a Trial
Clinical Trials Update, Market Analysis, and Projections for Dexamethasone, Neomycin Sulfate, and Polymyxin B Sulfate
Last updated: January 28, 2026
Summary
This report synthesizes the latest clinical trial developments, market dynamics, and growth projections pertaining to three key pharmaceuticals: Dexamethasone, Neomycin Sulfate, and Polymyxin B Sulfate. It provides an overview of recent research, regulatory updates, market size, competitive landscape, and future growth trends to aid strategic decision-making within the pharmaceutical sector.
Clinical Trials Update
Dexamethasone
Current Clinical Trials Active/Completed:
As of Q1 2023, over 150 active or completed clinical trials globally (ClinicalTrials.gov).
Recent focuses include COVID-19 treatment efficacy, inflammatory conditions, and neurological disorders.
Key Trials:
COVID-19: Confirmatory trials evaluating high-dose dexamethasone as a standard of care [1].
Inflammatory Diseases: Trials assessing safety and efficacy for rheumatoid arthritis and asthma.
Regulatory Status:
Widely approved; ongoing trials aim at expanding indications, especially in neurology and oncology.
Neomycin Sulfate
Current Clinical Trials Active/Completed:
Few new high-profile trials, mostly focused on topical formulations and resistance profiles.
Past trials omitted systemic uses due to toxicity concerns.
Neomycin Sulfate: Approved for topical use; systemic applications under limited regulation due to safety concerns.
Polymyxin B Sulfate: Approvals for critical infections expanded in China and US; global guidelines increasingly favor its use against MDR pathogens.
FAQs
What are the primary therapeutic uses for dexamethasone?
Dexamethasone is primarily used for anti-inflammatory, immunosuppressant, and diagnostic purposes, with recent emphasis on COVID-19 treatment and autoimmune diseases.
How is resistance impacting the market for Neomycin Sulfate?
Resistance has led to a decline in systemic use, limiting growth; however, topical applications remain stable with ongoing development of resistant infection formulations.
What drives the growth of Polymyxin B Sulfate in the coming years?
The global increase in MDR gram-negative bacterial infections and success in combination therapies are key drivers.
Are there significant safety concerns with Polymyxin B Sulfate?
Yes, nephrotoxicity and neurotoxicity remain concerns, but new dosing protocols and formulations are mitigating these risks.
What regional markets are expanding fastest for these drugs?
Asia-Pacific, especially China and India, are experiencing rapid growth due to increasing MDR infections and expanding healthcare infrastructure.
Key Takeaways
Dexamethasone remains a dominant, rapidly expanding corticosteroid with significant growth prospects driven by ongoing COVID-19 use and autoimmune indications.
Neomycin Sulfate holds a stable niche primarily in topical applications; systemic use remains limited due to toxicity, but innovation and resistance management provide some growth avenues.
Polymyxin B Sulfate is at the forefront of addressing MDR bacterial infections, with a projected CAGR of nearly 8%, supported by rising global incidence of resistant infections and regulatory approvals.
Market dynamics are driven by resistance profiles, regulatory pathways, and technological innovations in formulation and delivery mechanisms.
Strategic focus should align with emerging resistance patterns, regional growth opportunities, and ongoing clinical trial advancements, particularly in combination therapies for Polymyxin B.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
